Xarelto's primary patent protection in the United States is set to expire in 2026. This date refers to the expiration of the patent covering the drug's active ingredient, rivaroxaban [1].
What happens after the primary patent expires?
Following the expiration of the 2026 patent, the market for Xarelto could open to generic competition. This typically leads to a significant reduction in the drug's price as multiple manufacturers offer their versions [1].
Are there other patents protecting Xarelto?
While the 2026 patent is a key one, pharmaceutical companies often secure multiple patents covering various aspects of a drug, including its formulation, manufacturing process, and methods of use. These secondary patents can sometimes extend market exclusivity beyond the expiration of the primary patent [2]. For Xarelto, additional patents may influence when generic versions can fully enter the market [1][2].
Who makes Xarelto and what are its uses?
Xarelto (rivaroxaban) is manufactured by Bayer and Janssen Pharmaceuticals. It is an anticoagulant medication prescribed to prevent blood clots in various conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), and to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1].
Can biosimilars be developed for Xarelto?
Xarelto is a small molecule drug, not a biologic. Therefore, biosimilars, which are similar versions of biologic medications, are not applicable. The generic competition that arises after patent expiration involves chemically synthesized versions of the active ingredient [1].
What is the current market status for Xarelto?
Xarelto has been a widely prescribed anticoagulant. The anticipation of its patent expiration in 2026 is a significant event for the pharmaceutical market, potentially impacting both Bayer's revenue and the accessibility and cost of anticoagulant therapy for patients [1][2].